Trial · NCT02118714
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26 | Atrasentan | 23.5 | percentage of participants | ||
| Percentage of Participants Who Entered the Observation Period and Did Not Return to Within 15% of Baseline Sperm Concentration or Above During the 52-Week Observational Period | Atrasentan | 11.8 | percentage of participants | ||
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration | Atrasentan | Treatment Period Week 13 | 2.2 | Standard Deviation 42.21 | sperm * million per milliliter(X10^6/mL) |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration | Atrasentan | Treatment Period Week 26 | -10.6 | Standard Deviation 53.44 | sperm * million per milliliter(X10^6/mL) |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration | Atrasentan | Observation Period Week 13 | 35.8 | Standard Deviation 113.60 | sperm * million per milliliter(X10^6/mL) |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration | Atrasentan | Observation Period Week 26 | -16.5 | Standard Deviation 0.00 | sperm * million per milliliter(X10^6/mL) |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration | Atrasentan | Observation Period Week 39 | -27.5 | Standard Deviation 19.09 | sperm * million per milliliter(X10^6/mL) |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration | Atrasentan | Observation Period Week 52 | -25.8 | Standard Deviation 1.06 | sperm * million per milliliter(X10^6/mL) |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility | Atrasentan | Treatment Period Week 13 | -5.8 | Standard Deviation 13.65 | percent motility |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility | Atrasentan | Treatment Period Week 26 | -7.4 | Standard Deviation 15.77 | percent motility |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility | Atrasentan | Observation Period Week 13 | -0.3 | Standard Deviation 19.20 | percent motility |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility | Atrasentan | Observation Period Week 26 | -6.3 | Standard Deviation 5.30 | percent motility |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility | Atrasentan | Observation Period Week 39 | 10.8 | Standard Deviation 15.20 | percent motility |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility | Atrasentan | Observation Period Week 52 | 1.8 | Standard Deviation 16.62 | percent motility |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology | Atrasentan | Treatment Period Week 13 | -1.1 | Standard Deviation 4.78 | percentage of normal |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology | Atrasentan | Treatment Period Week 26 | -2.2 | Standard Deviation 7.54 | percentage of normal |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology | Atrasentan | Observation Period Week 13 | -0.8 | Standard Deviation 7.53 | percentage of normal |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology | Atrasentan | Observation Period Week 26 | -6.8 | Standard Deviation 0.35 | percentage of normal |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology | Atrasentan | Observation Period Week 39 | -2.3 | Standard Deviation 1.77 | percentage of normal |
| Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology | Atrasentan | Observation Period Week 52 | 1.8 | Standard Deviation 0.35 | percentage of normal |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02118714/results